aln-hsd
Nucleic acidexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 9, 2020 (NCT04565717)
Timeline
Indications
Mechanism of action
- 17-beta-hydroxysteroid dehydrogenase 13ANTISENSE INHIBITOR
antisense inhibitor - HSD17B13
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05519475 | Phase 2 | Oct 25, 2022 | Regeneron |
| NCT04565717 | Phase 1 | Oct 9, 2020 | Alnylam Pharmaceuticals |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Alnylam Pharmaceuticals | For profit | 1 | 1 | 1 | 2020 |
| Regeneron | For profit | 1 | 1 | 1 | 2022 |
2 organizations
Page 1 / 1